 
Clinical Division
Introduction
Bylaws
Officers
Meetings
Reports
Research in Humans
Compendium
Pharmacogenetics
|
Clinical Division:
Pharmacogenetics
Last Updated 1 February 2008
IUPHAR Division of Clinical Pharmacology -
Sub-Committee on Pharmacogenetics
Aims
• Development of a drug-related pharmacogenetic database
• Promoting exchange of pharmacogenetic knowledge by organisation of symposia and workshops in the
field of pharmacogenetics and –genomics
• Evaluation of the clinical impact of pharmacogenetics
| Members |
E-mail Address |
Ingolf Cascorbi, Kiel, Germany (Chair)
Laurent Bequemont, Paris, France
Ann Daly, PhD, Newcastle, UK
Magnus Ingelman-Sundberg, Stockholm, Sweden
Vural Özdemir, Montreal, Canada
Mathias Schwab, Stuttgart, Germany
Guilherme Suarez-Kurtz, Rio de Janeiro, Brazil
Toshiyuki Someya, Niigata, Japan
Andrew Somogyi, Adelaide, Australia
Bryn Williams-Jones, Montreal, Canada |
cascorbi@pharmakologie.uni-kiel.de
laurent.bequemont@chusa.jussieu.fr
a.k.daly@newcastle.ac.uk
magnus.ingelman-sundberg@ki.se
vural.ozdemir@umontreal.ca
matthias.schwab@ikp-stuttgart.de
kurtz@inca gov br
someya@med.niigata-u.ac.jp
andrew.somogyi@adelaide.edu.au
bryn.williams-jones@umontreal.ca |
Iuphar Division Of Clinical Pharmacology - Subcommittee On Pharmacogenetics
The subcommittee on pharmacogenetics was re-established in the summer of 2006 after the IUPHAR2006 conference in Beijing, China. It consists of an increasing number of distinguished scientists from different continents, covering expertise from molecular biology to ethical aspect of pharmacogenetics.
Background:
Pharmacotherapy optimization through individual drug therapy is one of the major goals of clinical medicine. Over the last decades it has been clearly shown that genetics play a significant role in the pharmacokinetics of drugs and there is an increasing understanding of the genetic background among individuals and ethnic groups with regard to drug efficacy and response. Pharmacogenetics has developed into one of the most important subfields of clinical pharmacology and plays a significant role in the drug development process.
Aims and scopes The subcommittee will
- Promote exchange of pharmacogenetic knowledge by organization of symposia and workshops in the field of pharmacogenetics and –genomics.
- Evaluate the clinical impact of pharmacogenetics
- Cooperate with drug-related pharmacogenetic database
- Create a population based “biobank” to conduct translational research in clinical pharmacogenomics
- Establish international collaborative clinical studies to investigate the benefits of pharmacogenetics.
- A compendium is under development addressing the following topics: Scientific basis of pharmacogenomics
- History of pharmacogenetics
- Basics of pharmacogenetics
- Developments of Pharmacogenomics
- Ethnical diversity in pharmacogenetics/genomics
- Ethical issues of pharmacogenetic information
- Usefulness of pharmacogenetics
- Approval process
- Pharmacogenetics in practice
- Data on genetic variances relevant for drug therapy
- Current recommendations of genotype-adapted drug therapy
First meetings of the subcommittee will take place on the occasion of the ASCPT2007 meeting in Anaheim, CA and the EACPT2007 congress in Amsterdam, The Netherlands.
The subcommittee cooperates with the Pacific Rim organization on Clinical Pharmacogenetics (PRACP), a society associated with IUPHAR. A satellite meeting on pharmacogenetics has been proposed for the CPT2008 congress in Quebec.
Ingolf Cascorbi - Speaker, Subcommittee on Pharmacogenetics
|